NKTR-255 is an investigational long-acting polymer-conjugated recombinant IL-15 receptor agonist designed to enhance anti-tumor immunity. It expands and activates natural killer and CD8+ T-cell populations and is being studied in relapsed/refractory hematologic malignancies and solid tumor settings. Development is ongoing in early-phase clinical programs.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05632809 |
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) |
RECRUITING | PHASE2 |
| NCT05327530 |
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04616196 |
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors |
COMPLETED | PHASE1/PHASE2 |
| NCT04136756 |
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma |
COMPLETED | PHASE1 |
| NCT03233854 |
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1 |
